Home > Clinical Trials
Check All Search

Saved trials

RECRUITING
NCT06578247
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
700 Enrollment(s)
292 Study location(s)
INTERVENTIONAL (PHASE3)
Leukemia
RECRUITING
NCT06210776
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
800 Enrollment(s)
54 Study location(s)
OBSERVATIONAL (None)
HER2-positive Breast Cancer


HER2-low Breast Cancer


Breast Cancer


Advanced Cancer
ACTIVE_NOT_RECRUITING
NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
490 Enrollment(s)
156 Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer, Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma
RECRUITING
NCT03661307
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
73 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia


Myelodysplastic Syndrome


Recurrent Acute Myeloid Leukemia


Recurrent Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia
COMPLETED
NCT06961331
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
86 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Metastatic HER2+ Advanced Breast Cancer
RECRUITING
NCT06819007
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
582 Enrollment(s)
138 Study location(s)
INTERVENTIONAL (PHASE3)
Ovarian Cancer
NOT_YET_RECRUITING
NCT07126561
Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers
43 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2
RECRUITING
NCT06899126
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
686 Enrollment(s)
100 Study location(s)
INTERVENTIONAL (PHASE3)
Non-small Cell Lung Cancer